S&P ASX All Technology

US Dollar vs AUD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

TNXP Tonix Pharmaceuticals Holding Corporation

0.1439

0.0045 (3.23%)

08 Oct 2024 - Closed

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Sep 2024 to Oct 2024

Click Here for more Tonix Pharmaceuticals Charts.

Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Oct 2023 to Oct 2024

Click Here for more Tonix Pharmaceuticals Charts.

Tonix Pharmaceuticals Holding Corporation News

Form EFFECT - Notice of Effectiveness
Tuesday 1 October 2024 (1 week ago) • Edgar (US Regulatory)

Tonix Pharmaceuticals Announces Participation in Endpoints Panel at the Long COVID Workshop and RECOVER TLC Workshop Convened by the Foundation for the National Institutes of Health (FNIH) and the National Institute of Allergy and Infectious Diseases (NIAI
Monday 30 September 2024 (1 week ago) • GlobeNewswire Inc.

Form 8-K - Current report
Friday 27 September 2024 (2 weeks ago) • Edgar (US Regulatory)

Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering the Subcutaneous Delivery of FDA-Approved Zembrace® SymTouch® to Treat Migraines
Friday 27 September 2024 (2 weeks ago) • GlobeNewswire Inc.

Form DEF 14A - Other definitive proxy statements
Tuesday 24 September 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 23 September 2024 (2 weeks ago) • Edgar (US Regulatory)

Tonix Pharmaceuticals Announces Data Presentations on TNX-102 SL for Fibromyalgia at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems (PDDS 2024)
Monday 23 September 2024 (2 weeks ago) • GlobeNewswire Inc.

Form S-3 - Registration statement under Securities Act of 1933
Saturday 21 September 2024 (2 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Thursday 19 September 2024 (3 weeks ago) • Edgar (US Regulatory)

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra® to Treat Migraines
Thursday 19 September 2024 (3 weeks ago) • GlobeNewswire Inc.

Form 8-K - Current report
Monday 16 September 2024 (3 weeks ago) • Edgar (US Regulatory)

Tonix Pharmaceuticals Announces That its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO’s Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency
Monday 16 September 2024 (3 weeks ago) • GlobeNewswire Inc.

More Tonix Pharmaceuticals Holding Corporation News Articles

S&P ASX 300 Metals and M...

Australian SE All Ordina...

National Australia Bank

JP Morgan Chase

Commonwealth Bank Of Aus...

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions